Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Dlabach

Sports Medicine Collierville, TN Medical Doctor

NPI 1689660375 CMS profile 121127

99 Market Center Dr, Collierville, TN 38017

Open in the dashboard

General payments

$503,962

9 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeffrey Dlabach of Collierville, TN is reported in the CMS Open Payments database as having received $503,962 across 9 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $77 2
2022 General $500,859 5
2019 General $3,026 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Dlabach
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Jeffrey Dlabach were reported at $77. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year Jeffrey Dlabach Sports Medicine median Middle half National median
2019 $3,026 $1,176 $199–$4,249 $163
2020 $0 $708 $96–$2,890 $114
2021 $0 $1,213 $152–$3,994 $132
2022 $500,859 $1,230 $159–$3,998 $149
2023 $0 $584 $146–$2,836 $160
2024 $0 $628 $163–$3,168 $164
2025 $77 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Triad Life Sciences Inc. $500,840 4 payments
  2. Gentleman Orthopedic Solutions $3,026 2 payments
  3. Smith+Nephew, Inc. $77 2 payments
  4. Axonics Modulation Technologies, Inc. $19 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Acquisitions $500,840 4 payments
  2. Education $3,026 2 payments
  3. Food and Beverage $95 3 payments
Products named General payments · program years 2019–2025
  1. RENASYS Touch $77 2 payments
  2. Axonics $19 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

646

Median for Orthopedic Surgery: 203

Drug cost

$6,811

Median for Orthopedic Surgery: $1,433

Branded share of claims

2.2%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 64 $2,563
Diclofenac Sodium Generic 73 $1,507
Methylprednisolone Generic 242 $1,463
Meloxicam Generic 145 $805
Tizanidine Hcl Generic 32 $169
Naproxen Generic 20 $105
Tramadol Hcl Generic 42 $89
Gabapentin Generic 14 $61
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 14 $50

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 65 billing codes

Paid by Medicare

$194,338

Of which drugs: $25,073

Medicare patients

404

Average age 73

Services billed

73,379

223 women, 181 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 72%
Ischemic heart disease 33%
Diabetes 23%
Cancer 16%
Chronic kidney disease 15%
Depression 14%
Atrial fibrillation 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, gelsyn-3, for intra-articular injection, 0.1 mg J7328 Office 63 47,383 $18,958
Injection, methylprednisolone acetate, 1 mg J1010 Office 169 23,091 $2,358
Injection, methylprednisolone acetate, 80 mg J1040 Office 75 105 $604
Injection, methylprednisolone acetate, 40 mg J1030 Office 12 19 $70

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

9 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record